newsfilter
← Latest News
GlobeNewswire·

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the